Infanrix Hexa + Prevenar (GSK)

Infanrix Hexa + Prevenar refers to the concomitant administration of two distinct pediatric vaccines: Infanrix Hexa, a hexavalent vaccine developed by GSK, and Prevenar (typically Prevenar 13), a pneumococcal conjugate vaccine developed by Pfizer. Infanrix Hexa provides protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b. Prevenar 13 provides protection against 13 serotypes of Streptococcus pneumoniae. This co-administration is a standard part of infant immunization schedules globally. Clinical studies have evaluated the immunogenicity and safety of giving these vaccines together, noting a slightly higher incidence of fever and febrile convulsions compared to separate administration, though the practice remains recommended for convenience and coverage.

Brand names

Prevenar 13Prevenar13Prevenar-13PCV13PCV-13PCV 13

Other names

DTaP-HBV-IPV/Hib + PCV13DTPa-HBV-IPV/Hib + PCV13hexavalent vaccine + pneumococcal conjugate vaccine